Marker utility for combination therapy

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Melanoma is a heterogeneous disease for which monotherapies are likely to fail in the majority of patients due to genomic variations between individuals. Novel treatments, such as vemurafenib and ipilimumab, offer clinical promise in metastatic melanoma and the increased potential for combined therapeutic strategies, necessary given the differences in response between patients. Together with these new approaches, the development of clinically relevant biomarkers that predict treatment outcomes are required to ensure these new therapies are targeted at those patients most likely to benefit. Here we review the utility of some potential biomarkers of treatment response in patients with metastatic melanoma.

Original languageEnglish
Title of host publicationMethods in Molecular Biology
Pages97-115
Number of pages19
Volume1102
DOIs
Publication statusPublished - 2014

Publication series

NameMethods in Molecular Biology
Volume1102
ISSN (Print)10643745

Fingerprint

Melanoma
Biomarkers
Therapeutics
ipilimumab
PLX4032

Keywords

  • Anti-PD1
  • Biomarkers
  • BRAF inhibitors
  • Combination therapy
  • Immune therapy
  • Ipilimumab
  • Metastatic melanoma
  • Molecular profiling
  • Vemurafenib

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Simeone, E., Grimaldi, A. M., & Ascierto, P. A. (2014). Marker utility for combination therapy. In Methods in Molecular Biology (Vol. 1102, pp. 97-115). (Methods in Molecular Biology; Vol. 1102). https://doi.org/10.1007/978-1-62703-727-3_7

Marker utility for combination therapy. / Simeone, Ester; Grimaldi, Antonio M.; Ascierto, Paolo A.

Methods in Molecular Biology. Vol. 1102 2014. p. 97-115 (Methods in Molecular Biology; Vol. 1102).

Research output: Chapter in Book/Report/Conference proceedingChapter

Simeone, E, Grimaldi, AM & Ascierto, PA 2014, Marker utility for combination therapy. in Methods in Molecular Biology. vol. 1102, Methods in Molecular Biology, vol. 1102, pp. 97-115. https://doi.org/10.1007/978-1-62703-727-3_7
Simeone E, Grimaldi AM, Ascierto PA. Marker utility for combination therapy. In Methods in Molecular Biology. Vol. 1102. 2014. p. 97-115. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-62703-727-3_7
Simeone, Ester ; Grimaldi, Antonio M. ; Ascierto, Paolo A. / Marker utility for combination therapy. Methods in Molecular Biology. Vol. 1102 2014. pp. 97-115 (Methods in Molecular Biology).
@inbook{7d73e53f2a9f445fb1416108b39f9b8f,
title = "Marker utility for combination therapy",
abstract = "Melanoma is a heterogeneous disease for which monotherapies are likely to fail in the majority of patients due to genomic variations between individuals. Novel treatments, such as vemurafenib and ipilimumab, offer clinical promise in metastatic melanoma and the increased potential for combined therapeutic strategies, necessary given the differences in response between patients. Together with these new approaches, the development of clinically relevant biomarkers that predict treatment outcomes are required to ensure these new therapies are targeted at those patients most likely to benefit. Here we review the utility of some potential biomarkers of treatment response in patients with metastatic melanoma.",
keywords = "Anti-PD1, Biomarkers, BRAF inhibitors, Combination therapy, Immune therapy, Ipilimumab, Metastatic melanoma, Molecular profiling, Vemurafenib",
author = "Ester Simeone and Grimaldi, {Antonio M.} and Ascierto, {Paolo A.}",
year = "2014",
doi = "10.1007/978-1-62703-727-3_7",
language = "English",
isbn = "9781627037266",
volume = "1102",
series = "Methods in Molecular Biology",
pages = "97--115",
booktitle = "Methods in Molecular Biology",

}

TY - CHAP

T1 - Marker utility for combination therapy

AU - Simeone, Ester

AU - Grimaldi, Antonio M.

AU - Ascierto, Paolo A.

PY - 2014

Y1 - 2014

N2 - Melanoma is a heterogeneous disease for which monotherapies are likely to fail in the majority of patients due to genomic variations between individuals. Novel treatments, such as vemurafenib and ipilimumab, offer clinical promise in metastatic melanoma and the increased potential for combined therapeutic strategies, necessary given the differences in response between patients. Together with these new approaches, the development of clinically relevant biomarkers that predict treatment outcomes are required to ensure these new therapies are targeted at those patients most likely to benefit. Here we review the utility of some potential biomarkers of treatment response in patients with metastatic melanoma.

AB - Melanoma is a heterogeneous disease for which monotherapies are likely to fail in the majority of patients due to genomic variations between individuals. Novel treatments, such as vemurafenib and ipilimumab, offer clinical promise in metastatic melanoma and the increased potential for combined therapeutic strategies, necessary given the differences in response between patients. Together with these new approaches, the development of clinically relevant biomarkers that predict treatment outcomes are required to ensure these new therapies are targeted at those patients most likely to benefit. Here we review the utility of some potential biomarkers of treatment response in patients with metastatic melanoma.

KW - Anti-PD1

KW - Biomarkers

KW - BRAF inhibitors

KW - Combination therapy

KW - Immune therapy

KW - Ipilimumab

KW - Metastatic melanoma

KW - Molecular profiling

KW - Vemurafenib

UR - http://www.scopus.com/inward/record.url?scp=84891769148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891769148&partnerID=8YFLogxK

U2 - 10.1007/978-1-62703-727-3_7

DO - 10.1007/978-1-62703-727-3_7

M3 - Chapter

C2 - 24258976

AN - SCOPUS:84891769148

SN - 9781627037266

VL - 1102

T3 - Methods in Molecular Biology

SP - 97

EP - 115

BT - Methods in Molecular Biology

ER -